Pharmaceutical

Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks

The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) this year amid ongoing macroeconomic uncertainties, fluctuating interest rates, and evolving Medicare drug price negotiations.

Apr 27, 2024 - 00:00
Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks
The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) this year amid ongoing macroeconomic uncertainties, fluctuating interest rates, and evolving Medicare drug price negotiations.
Read the original article

Tags:

Previous Article

The privileged status of orphan medicines in Germany

Next Article

Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

New definition of a human embryo proposed amid rapid scientific advances

New definition of a human embryo proposed amid rapid sc...

Aug 17, 2023

STAT+: Republicans consider a new attack on Biden ‘march-in’ plan for lower drug prices

STAT+: Republicans consider a new attack on Biden ‘marc...

Mar 6, 2024

Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate

Alvotech’s AVT05 in phase III rheumatoid arthritis stud...

Sep 23, 2023